There are a number of potential blockbuster drugs in the pipeline that are expected to reach the market in 2004. Among them: Pfizer's Pregabalin for epilepsy and pain; Genentech and Roche's Avastin for cancer; Pfizer's Caduet and AstraZeneca's Exanta for cardiovascular treatment and Eli Lilly's Cymbalta for depression.

Full Story:

Related Summaries